Systemic Delivery of Bc12‐Targeting siRNA by DNA Nanoparticles Suppresses Cancer Cell Growth. Issue 50 (15th November 2017)

• Record Type: Journal Article
• Authors: Rahman, Mohammad Aminur; Wang, Pengfei; Zhao, Zhixiang; Wang, Dongsheng; Nannapaneni, Sreenivas; Zhang, Chao; Chen, Zhengjia; Griffith, Christopher C.; Hurwitz, Selwyn J.; Chen, Zhuo G.; Ke, Yonggang; Shin, Dong M.
• Is Part Of: Angewandte Chemie international edition. Volume 56:Issue 50(2017)
• Page Start: 16023
• Page End: 16027
• Publication Date: 2017-11-15
• Subjects: Bcl2 -- cancer therapy -- DNA nanotechnology -- nanoparticles -- siRNA delivery; Chemistry -- Periodicals; 540
• DOI: 10.1002/anie.201709485
• Languages: English
• ISSNs: 1433-7851

Abstract

Abstract: Short interfering RNA (siRNA) is a promising molecular tool for cancer therapy, but its clinical success is limited by the lack of robust in vivo delivery systems. Rationally designed DNA nanoparticles (DNPs) have emerged as facile delivery vehicles because their physicochemical properties can be precisely controlled. Nonetheless, few studies have used DNPs to deliver siRNAs in vivo, and none has demonstrated therapeutic efficacy. Herein, we constructed a number of DNPs of rectangular and tubular shapes with varied dimensions using the modular DNA brick method for the systemic delivery of siRNA that targets anti‐apoptotic protein Bcl2. The siRNA delivered by the DNPs inhibited cell growth both in vitro and in vivo, which suppressed tumor growth in a xenograft model that specifically correlated with Bcl2 depletion. This study suggests that DNPs are effective tools for the systemic delivery of therapeutic siRNA and have great potential for further clinical translation. Abstract : DNPs can deliver : DNA nanoparticles (DNPs) were utilized as vehicles for the systemic delivery of siRNA to suppress tumor growth by specifically knocking down the anti‐apoptotic protein Bcl2.